abvc-logo-nasdaq-440x386 (1).png
ABVC BioPharma ADHD Phase II Part 2 Clinical Study First Subject Treated
10. Mai 2022 08:30 ET | ABVC BioPharma, Inc.
FREMONT, CA, May 10, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire – ABVC Biopharma, Inc. (NASDAQ: ABVC), a clinical stage biopharmaceutical company developing therapeutic solutions in...
abvc-logo-nasdaq-440x386 (1).png
ABVC BioPharma Completes Site Initiation Visits and Begins Enrollments for ADHD Phase II Part 2 Clinical Study
28. April 2022 08:30 ET | ABVC BioPharma, Inc.
FREMONT, CA, April 28, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire - ABVC Biopharma, Inc. (NASDAQ: ABVC), a clinical stage biopharmaceutical company developing therapeutic solutions in...